You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: cholinesterase inhibitors may be effective in Alzheimer’s disease

https://doi.org/10.1136/ebm.11.1.23

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005;331:321–7.
    OpenUrlAbstract/FREE Full Text

    
 
 Q In patients with Alzheimer’s disease (AD), does treatment with cholinesterase inhibitors (donepezil, rivastigmine, or galantamine) improve clinical outcomes?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Geriatrics ★★★★★★★ Psychiatry ★★★★★★☆ Neurology ★★★★★★☆

    METHODS

    Embedded ImageData sources:

    Medline (1989 to November 2004), EMBASE/Excerpta Medica (1989 to November 2004), the Cochrane Database of Systematic Reviews, and bibliographies of relevant studies.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) (published in any language) that compared cholinesterase inhibitors (donepezil, rivastigmine, or galantamine) with placebo in patients with AD. Studies that did not examine clinical outcomes or focused on vascular dementia were excluded.

    Embedded ImageOutcomes:

    measures of clinical outcome included Alzheimer’s Disease Assessment-Cognitive Subscale, Clinician’s Interview-Based Impression …

    View Full Text

    Footnotes

    • For correspondence: Dr H Kaduszkiewicz, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. kaduszki{at}uke.uni-hamburg.de

    • Source of funding: not stated.